GLP-1 and underlying beneficial actions in alzheimer's disease, hypertension, and NASH
QX Li, H Gao, YX Guo, BY Wang, R Hua… - Frontiers in …, 2021 - frontiersin.org
GLP-1 is derived from intestinal L cells, which takes effect through binding to GLP-1R and is
inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). Since its discovery, GLP-1 has …
inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). Since its discovery, GLP-1 has …
Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis
GF Piccoli, LA Mesquita, C Stein, M Aziz… - The Journal of …, 2021 - academic.oup.com
Context Risk of cancer is a major concern in the development of drugs for the treatment of
obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical …
obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical …
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup …
RE Pratley, MJ Crowley, M Gislum, CL Hertz… - Diabetes Therapy, 2021 - Springer
Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1
receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide …
receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide …
Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and …
S Jia, Z Wang, R Han, Z Zhang, Y Li, X Qin, M Zhao… - Acta Diabetologica, 2021 - Springer
Purpose Although there are many different methods of treating type 2 diabetes (T2D), it is
still difficult to draw coincident conclusions concerning the efficacy and safety of different …
still difficult to draw coincident conclusions concerning the efficacy and safety of different …
Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: a network meta-analysis of randomized, active comparator-controlled trials
E Mannucci, L Naletto, G Vaccaro, A Silverii… - Nutrition, Metabolism …, 2021 - Elsevier
Aim Aim of the present network meta-analysis (NMA) is the comparison across glucose-
lowering drugs (GLA) concerning their effects on glucose control, body weight …
lowering drugs (GLA) concerning their effects on glucose control, body weight …
Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and meta-analysis
W Jianping, Z Xuelian, W Anjiang… - Journal of Clinical …, 2021 - journals.lww.com
Background: Clinical trials examining the therapeutic benefits of glucagon-like peptide-1
receptor agonists (GLP-1RA) on patients with metabolic associated fatty liver disease …
receptor agonists (GLP-1RA) on patients with metabolic associated fatty liver disease …
Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 …
C Campos, J Unger - Postgraduate Medicine, 2021 - Taylor & Francis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors
(DPP4is) exert their effects via the incretin system, which augments glucose-dependent …
(DPP4is) exert their effects via the incretin system, which augments glucose-dependent …
[HTML][HTML] Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance
A Rezki, M Fysekidis, S Chiheb, E Vicaut… - Nutrition, Metabolism …, 2021 - Elsevier
Background and aims Dipeptidyl-peptidase inhibitors might be useful in type 2 diabetes
prevention. ACCES (ACute and Chronic Effects of Saxagliptin) was a randomized, placebo …
prevention. ACCES (ACute and Chronic Effects of Saxagliptin) was a randomized, placebo …
Switching from daily DPP-4 inhibitor to once-weekly GLP-1 receptor activator dulaglutide significantly ameliorates glycemic control in subjects with poorly controlled …
J Sanada, T Kimura, M Shimoda, A Tomita… - Frontiers in …, 2021 - frontiersin.org
Aim At present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2
diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly …
diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly …
[HTML][HTML] Beta-cell autophagy under the scope of hypoglycemic drugs; possible mechanism as a novel therapeutic target
BA Marzoog, TI Vlasova - Ожирение и метаболизм, 2021 - cyberleninka.ru
Physiologically, autophagy is a major protective mechanism of β-cells from apoptosis,
through can reserve normal β-cell mass and inhibit the progression of β-cells destruction …
through can reserve normal β-cell mass and inhibit the progression of β-cells destruction …